nodes	percent_of_prediction	percent_of_DWPC	metapath
Lansoprazole—CYP2C18—prostate cancer	0.105	0.333	CbGaD
Lansoprazole—CYP1B1—prostate cancer	0.0869	0.275	CbGaD
Lansoprazole—CYP4A11—Estrone—prostate cancer	0.0517	0.119	CbGbCtD
Lansoprazole—CYP2C19—prostate cancer	0.0471	0.149	CbGaD
Lansoprazole—CYP1A1—prostate cancer	0.0469	0.149	CbGaD
Lansoprazole—MAPT—Docetaxel—prostate cancer	0.0465	0.107	CbGbCtD
Lansoprazole—CYP3A4—prostate cancer	0.03	0.0948	CbGaD
Lansoprazole—CYP1B1—Flutamide—prostate cancer	0.0297	0.0682	CbGbCtD
Lansoprazole—CYP1B1—Estrone—prostate cancer	0.0215	0.0493	CbGbCtD
Lansoprazole—CYP1A1—Flutamide—prostate cancer	0.013	0.0299	CbGbCtD
Lansoprazole—CYP1B1—Mitoxantrone—prostate cancer	0.0128	0.0293	CbGbCtD
Lansoprazole—CYP1B1—Estradiol—prostate cancer	0.0123	0.0283	CbGbCtD
Lansoprazole—ABCG2—Cabazitaxel—prostate cancer	0.0104	0.024	CbGbCtD
Lansoprazole—ABCG2—Estrone—prostate cancer	0.0102	0.0235	CbGbCtD
Lansoprazole—CYP1A1—Estrone—prostate cancer	0.00942	0.0217	CbGbCtD
Lansoprazole—CYP2C8—Nilutamide—prostate cancer	0.00908	0.0209	CbGbCtD
Lansoprazole—CYP2C19—Nilutamide—prostate cancer	0.00761	0.0175	CbGbCtD
Lansoprazole—CYP2C19—Bicalutamide—prostate cancer	0.00761	0.0175	CbGbCtD
Lansoprazole—CYP2C8—Abiraterone—prostate cancer	0.00752	0.0173	CbGbCtD
Lansoprazole—CYP1B1—Docetaxel—prostate cancer	0.00737	0.0169	CbGbCtD
Lansoprazole—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.00701	0.0161	CbGbCtD
Lansoprazole—ABCG2—Conjugated Estrogens—prostate cancer	0.00668	0.0153	CbGbCtD
Lansoprazole—CYP2C9—Nilutamide—prostate cancer	0.00633	0.0145	CbGbCtD
Lansoprazole—CYP2C9—Bicalutamide—prostate cancer	0.00633	0.0145	CbGbCtD
Lansoprazole—CYP2C19—Flutamide—prostate cancer	0.00631	0.0145	CbGbCtD
Lansoprazole—ABCG2—Mitoxantrone—prostate cancer	0.00607	0.0139	CbGbCtD
Lansoprazole—ABCG2—Estradiol—prostate cancer	0.00586	0.0135	CbGbCtD
Lansoprazole—CYP1A2—Flutamide—prostate cancer	0.00582	0.0134	CbGbCtD
Lansoprazole—CYP2D6—Bicalutamide—prostate cancer	0.00579	0.0133	CbGbCtD
Lansoprazole—ABCB1—Estramustine—prostate cancer	0.00571	0.0131	CbGbCtD
Lansoprazole—CYP2C8—Cabazitaxel—prostate cancer	0.00556	0.0128	CbGbCtD
Lansoprazole—CYP1B1—Doxorubicin—prostate cancer	0.00549	0.0126	CbGbCtD
Lansoprazole—CYP1A1—Estradiol—prostate cancer	0.00541	0.0124	CbGbCtD
Lansoprazole—CYP2C8—Ethinyl Estradiol—prostate cancer	0.00485	0.0111	CbGbCtD
Lansoprazole—CYP2D6—Abiraterone—prostate cancer	0.0048	0.011	CbGbCtD
Lansoprazole—CYP1A2—Estrone—prostate cancer	0.00421	0.00967	CbGbCtD
Lansoprazole—ABCG2—Etoposide—prostate cancer	0.00383	0.0088	CbGbCtD
Lansoprazole—CYP2C9—Estrone—prostate cancer	0.00379	0.00871	CbGbCtD
Lansoprazole—ABCB1—Cabazitaxel—prostate cancer	0.00377	0.00865	CbGbCtD
Lansoprazole—CYP3A4—Bicalutamide—prostate cancer	0.00368	0.00846	CbGbCtD
Lansoprazole—ABCB1—Estrone—prostate cancer	0.00368	0.00846	CbGbCtD
Lansoprazole—ABCG2—Docetaxel—prostate cancer	0.0035	0.00805	CbGbCtD
Lansoprazole—CYP3A4—Estramustine—prostate cancer	0.00342	0.00786	CbGbCtD
Lansoprazole—ABCB1—Ethinyl Estradiol—prostate cancer	0.00328	0.00754	CbGbCtD
Lansoprazole—CYP2C8—Estradiol—prostate cancer	0.00312	0.00718	CbGbCtD
Lansoprazole—CYP3A4—Abiraterone—prostate cancer	0.00305	0.00701	CbGbCtD
Lansoprazole—CYP3A4—Flutamide—prostate cancer	0.00305	0.00701	CbGbCtD
Lansoprazole—CYP2C9—Capecitabine—prostate cancer	0.00287	0.0066	CbGbCtD
Lansoprazole—CYP1A2—Conjugated Estrogens—prostate cancer	0.00275	0.00633	CbGbCtD
Lansoprazole—CYP2C19—Estradiol—prostate cancer	0.00262	0.00602	CbGbCtD
Lansoprazole—ABCG2—Doxorubicin—prostate cancer	0.00261	0.006	CbGbCtD
Lansoprazole—CYP1A2—Estradiol—prostate cancer	0.00242	0.00556	CbGbCtD
Lansoprazole—ABCB1—Conjugated Estrogens—prostate cancer	0.00241	0.00553	CbGbCtD
Lansoprazole—CYP3A4—Cabazitaxel—prostate cancer	0.00226	0.00518	CbGbCtD
Lansoprazole—CYP2C19—Prednisone—prostate cancer	0.00225	0.00518	CbGbCtD
Lansoprazole—CYP3A4—Estrone—prostate cancer	0.00221	0.00507	CbGbCtD
Lansoprazole—ABCB1—Mitoxantrone—prostate cancer	0.00219	0.00503	CbGbCtD
Lansoprazole—CYP2C9—Estradiol—prostate cancer	0.00218	0.00501	CbGbCtD
Lansoprazole—ABCB1—Estradiol—prostate cancer	0.00211	0.00486	CbGbCtD
Lansoprazole—CYP2C8—Etoposide—prostate cancer	0.00204	0.00469	CbGbCtD
Lansoprazole—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00197	0.00452	CbGbCtD
Lansoprazole—MAPT—prostate gland—prostate cancer	0.00196	0.102	CbGeAlD
Lansoprazole—ABCB1—Prednisone—prostate cancer	0.00182	0.00418	CbGbCtD
Lansoprazole—CYP1A2—Etoposide—prostate cancer	0.00158	0.00363	CbGbCtD
Lansoprazole—CYP3A4—Conjugated Estrogens—prostate cancer	0.00144	0.00332	CbGbCtD
Lansoprazole—CYP2C19—urine—prostate cancer	0.00142	0.0739	CbGeAlD
Lansoprazole—ABCB1—Etoposide—prostate cancer	0.00138	0.00317	CbGbCtD
Lansoprazole—CYP3A4—Mitoxantrone—prostate cancer	0.00131	0.00301	CbGbCtD
Lansoprazole—CYP3A4—Estradiol—prostate cancer	0.00127	0.00291	CbGbCtD
Lansoprazole—ABCB1—Docetaxel—prostate cancer	0.00126	0.0029	CbGbCtD
Lansoprazole—CYP4A11—renal system—prostate cancer	0.00123	0.0642	CbGeAlD
Lansoprazole—CYP1A2—urine—prostate cancer	0.00116	0.0603	CbGeAlD
Lansoprazole—CYP2C9—urine—prostate cancer	0.0011	0.0573	CbGeAlD
Lansoprazole—CYP3A4—Prednisone—prostate cancer	0.00109	0.0025	CbGbCtD
Lansoprazole—ATP4A—epithelium—prostate cancer	0.00107	0.0558	CbGeAlD
Lansoprazole—ATP4A—renal system—prostate cancer	0.000993	0.0517	CbGeAlD
Lansoprazole—ABCB1—Doxorubicin—prostate cancer	0.000941	0.00216	CbGbCtD
Lansoprazole—CYP2D6—Doxorubicin—prostate cancer	0.000887	0.00204	CbGbCtD
Lansoprazole—MAPT—testis—prostate cancer	0.000864	0.045	CbGeAlD
Lansoprazole—CYP3A4—urine—prostate cancer	0.000838	0.0437	CbGeAlD
Lansoprazole—CYP3A4—Etoposide—prostate cancer	0.000827	0.0019	CbGbCtD
Lansoprazole—CYP2D6—urine—prostate cancer	0.000825	0.043	CbGeAlD
Lansoprazole—CYP3A4—Docetaxel—prostate cancer	0.000757	0.00174	CbGbCtD
Lansoprazole—ATP4A—testis—prostate cancer	0.000642	0.0334	CbGeAlD
Lansoprazole—MAPT—lymph node—prostate cancer	0.000627	0.0326	CbGeAlD
Lansoprazole—CYP1B1—prostate gland—prostate cancer	0.00058	0.0302	CbGeAlD
Lansoprazole—CYP3A4—Doxorubicin—prostate cancer	0.000564	0.0013	CbGbCtD
Lansoprazole—Thiabendazole—CYP1A1—prostate cancer	0.000549	0.209	CrCbGaD
Lansoprazole—ABCG2—prostate gland—prostate cancer	0.000432	0.0225	CbGeAlD
Lansoprazole—CYP1B1—renal system—prostate cancer	0.000395	0.0206	CbGeAlD
Lansoprazole—ABCG2—seminal vesicle—prostate cancer	0.000365	0.019	CbGeAlD
Lansoprazole—Omeprazole—CYP2C18—prostate cancer	0.000315	0.12	CrCbGaD
Lansoprazole—CYP2C8—renal system—prostate cancer	0.000303	0.0158	CbGeAlD
Lansoprazole—CYP1A1—epithelium—prostate cancer	0.000301	0.0157	CbGeAlD
Lansoprazole—ABCG2—urethra—prostate cancer	0.000289	0.0151	CbGeAlD
Lansoprazole—CYP1A2—renal system—prostate cancer	0.000283	0.0148	CbGeAlD
Lansoprazole—CYP1A1—renal system—prostate cancer	0.000279	0.0146	CbGeAlD
Lansoprazole—CYP1A1—urethra—prostate cancer	0.000275	0.0143	CbGeAlD
Lansoprazole—Omeprazole—CYP1B1—prostate cancer	0.000261	0.0992	CrCbGaD
Lansoprazole—CYP1B1—testis—prostate cancer	0.000256	0.0133	CbGeAlD
Lansoprazole—Esomeprazole—CYP2C19—prostate cancer	0.00024	0.0913	CrCbGaD
Lansoprazole—ABCG2—bone marrow—prostate cancer	0.000223	0.0116	CbGeAlD
Lansoprazole—ABCB1—prostate gland—prostate cancer	0.000213	0.0111	CbGeAlD
Lansoprazole—CYP3A4—renal system—prostate cancer	0.000205	0.0107	CbGeAlD
Lansoprazole—CYP2D6—renal system—prostate cancer	0.000202	0.0105	CbGeAlD
Lansoprazole—CYP2C8—testis—prostate cancer	0.000196	0.0102	CbGeAlD
Lansoprazole—ABCG2—testis—prostate cancer	0.00019	0.00991	CbGeAlD
Lansoprazole—CYP1B1—lymph node—prostate cancer	0.000185	0.00965	CbGeAlD
Lansoprazole—ABCB1—seminal vesicle—prostate cancer	0.00018	0.00939	CbGeAlD
Lansoprazole—Pantoprazole—CYP2C19—prostate cancer	0.000173	0.066	CrCbGaD
Lansoprazole—Rabeprazole—CYP2C19—prostate cancer	0.000173	0.066	CrCbGaD
Lansoprazole—Rabeprazole—CYP1A1—prostate cancer	0.000173	0.0657	CrCbGaD
Lansoprazole—ABCB1—epithelium—prostate cancer	0.000157	0.00815	CbGeAlD
Lansoprazole—Esomeprazole—CYP3A4—prostate cancer	0.000153	0.058	CrCbGaD
Lansoprazole—ABCB1—renal system—prostate cancer	0.000145	0.00756	CbGeAlD
Lansoprazole—ABCB1—urethra—prostate cancer	0.000143	0.00743	CbGeAlD
Lansoprazole—Omeprazole—CYP2C19—prostate cancer	0.000141	0.0538	CrCbGaD
Lansoprazole—Omeprazole—CYP1A1—prostate cancer	0.000141	0.0536	CrCbGaD
Lansoprazole—ABCG2—lymph node—prostate cancer	0.000138	0.00719	CbGeAlD
Lansoprazole—CYP1A1—lymph node—prostate cancer	0.000131	0.00682	CbGeAlD
Lansoprazole—CYP2D6—testis—prostate cancer	0.00013	0.0068	CbGeAlD
Lansoprazole—Pantoprazole—CYP3A4—prostate cancer	0.00011	0.042	CrCbGaD
Lansoprazole—Rabeprazole—CYP3A4—prostate cancer	0.00011	0.042	CrCbGaD
Lansoprazole—ABCB1—bone marrow—prostate cancer	0.00011	0.00572	CbGeAlD
Lansoprazole—ABCB1—testis—prostate cancer	9.38e-05	0.00489	CbGeAlD
Lansoprazole—Omeprazole—CYP3A4—prostate cancer	8.99e-05	0.0342	CrCbGaD
Lansoprazole—ABCB1—lymph node—prostate cancer	6.8e-05	0.00354	CbGeAlD
Lansoprazole—Discomfort—Prednisone—prostate cancer	1.37e-05	0.000101	CcSEcCtD
Lansoprazole—Eye disorder—Epirubicin—prostate cancer	1.37e-05	0.000101	CcSEcCtD
Lansoprazole—Hypersensitivity—Etoposide—prostate cancer	1.37e-05	0.000101	CcSEcCtD
Lansoprazole—Tinnitus—Epirubicin—prostate cancer	1.37e-05	0.000101	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Capecitabine—prostate cancer	1.36e-05	0.000101	CcSEcCtD
Lansoprazole—Cardiac disorder—Epirubicin—prostate cancer	1.36e-05	0.0001	CcSEcCtD
Lansoprazole—Rhinitis—Doxorubicin—prostate cancer	1.36e-05	0.0001	CcSEcCtD
Lansoprazole—Dyspepsia—Docetaxel—prostate cancer	1.36e-05	0.0001	CcSEcCtD
Lansoprazole—Hepatitis—Doxorubicin—prostate cancer	1.36e-05	0.0001	CcSEcCtD
Lansoprazole—Insomnia—Capecitabine—prostate cancer	1.35e-05	9.99e-05	CcSEcCtD
Lansoprazole—Hypoaesthesia—Doxorubicin—prostate cancer	1.35e-05	9.97e-05	CcSEcCtD
Lansoprazole—Pharyngitis—Doxorubicin—prostate cancer	1.35e-05	9.94e-05	CcSEcCtD
Lansoprazole—Paraesthesia—Capecitabine—prostate cancer	1.34e-05	9.91e-05	CcSEcCtD
Lansoprazole—Decreased appetite—Docetaxel—prostate cancer	1.34e-05	9.91e-05	CcSEcCtD
Lansoprazole—Urinary tract disorder—Doxorubicin—prostate cancer	1.34e-05	9.89e-05	CcSEcCtD
Lansoprazole—Oedema peripheral—Doxorubicin—prostate cancer	1.34e-05	9.87e-05	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Docetaxel—prostate cancer	1.33e-05	9.85e-05	CcSEcCtD
Lansoprazole—Asthenia—Etoposide—prostate cancer	1.33e-05	9.85e-05	CcSEcCtD
Lansoprazole—Connective tissue disorder—Doxorubicin—prostate cancer	1.33e-05	9.84e-05	CcSEcCtD
Lansoprazole—Dyspnoea—Capecitabine—prostate cancer	1.33e-05	9.84e-05	CcSEcCtD
Lansoprazole—Anaphylactic shock—Prednisone—prostate cancer	1.33e-05	9.84e-05	CcSEcCtD
Lansoprazole—Oedema—Prednisone—prostate cancer	1.33e-05	9.84e-05	CcSEcCtD
Lansoprazole—Fatigue—Docetaxel—prostate cancer	1.33e-05	9.83e-05	CcSEcCtD
Lansoprazole—Angiopathy—Epirubicin—prostate cancer	1.33e-05	9.82e-05	CcSEcCtD
Lansoprazole—Urethral disorder—Doxorubicin—prostate cancer	1.33e-05	9.82e-05	CcSEcCtD
Lansoprazole—Nausea—Mitoxantrone—prostate cancer	1.33e-05	9.8e-05	CcSEcCtD
Lansoprazole—Immune system disorder—Epirubicin—prostate cancer	1.32e-05	9.78e-05	CcSEcCtD
Lansoprazole—Infection—Prednisone—prostate cancer	1.32e-05	9.77e-05	CcSEcCtD
Lansoprazole—Mediastinal disorder—Epirubicin—prostate cancer	1.32e-05	9.76e-05	CcSEcCtD
Lansoprazole—Constipation—Docetaxel—prostate cancer	1.32e-05	9.75e-05	CcSEcCtD
Lansoprazole—Pain—Docetaxel—prostate cancer	1.32e-05	9.75e-05	CcSEcCtD
Lansoprazole—Dyspepsia—Capecitabine—prostate cancer	1.32e-05	9.72e-05	CcSEcCtD
Lansoprazole—Chills—Epirubicin—prostate cancer	1.32e-05	9.71e-05	CcSEcCtD
Lansoprazole—Pruritus—Etoposide—prostate cancer	1.31e-05	9.71e-05	CcSEcCtD
Lansoprazole—Shock—Prednisone—prostate cancer	1.31e-05	9.68e-05	CcSEcCtD
Lansoprazole—Arrhythmia—Epirubicin—prostate cancer	1.31e-05	9.67e-05	CcSEcCtD
Lansoprazole—Visual impairment—Doxorubicin—prostate cancer	1.31e-05	9.65e-05	CcSEcCtD
Lansoprazole—Nervous system disorder—Prednisone—prostate cancer	1.31e-05	9.65e-05	CcSEcCtD
Lansoprazole—Tachycardia—Prednisone—prostate cancer	1.3e-05	9.6e-05	CcSEcCtD
Lansoprazole—Decreased appetite—Capecitabine—prostate cancer	1.3e-05	9.6e-05	CcSEcCtD
Lansoprazole—Alopecia—Epirubicin—prostate cancer	1.3e-05	9.57e-05	CcSEcCtD
Lansoprazole—Skin disorder—Prednisone—prostate cancer	1.29e-05	9.55e-05	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Capecitabine—prostate cancer	1.29e-05	9.53e-05	CcSEcCtD
Lansoprazole—Fatigue—Capecitabine—prostate cancer	1.29e-05	9.52e-05	CcSEcCtD
Lansoprazole—Hyperhidrosis—Prednisone—prostate cancer	1.29e-05	9.51e-05	CcSEcCtD
Lansoprazole—Mental disorder—Epirubicin—prostate cancer	1.28e-05	9.49e-05	CcSEcCtD
Lansoprazole—Erythema multiforme—Doxorubicin—prostate cancer	1.28e-05	9.47e-05	CcSEcCtD
Lansoprazole—Pain—Capecitabine—prostate cancer	1.28e-05	9.44e-05	CcSEcCtD
Lansoprazole—Constipation—Capecitabine—prostate cancer	1.28e-05	9.44e-05	CcSEcCtD
Lansoprazole—Erythema—Epirubicin—prostate cancer	1.28e-05	9.43e-05	CcSEcCtD
Lansoprazole—Malnutrition—Epirubicin—prostate cancer	1.28e-05	9.43e-05	CcSEcCtD
Lansoprazole—Feeling abnormal—Docetaxel—prostate cancer	1.27e-05	9.4e-05	CcSEcCtD
Lansoprazole—Diarrhoea—Etoposide—prostate cancer	1.27e-05	9.39e-05	CcSEcCtD
Lansoprazole—Anorexia—Prednisone—prostate cancer	1.27e-05	9.38e-05	CcSEcCtD
Lansoprazole—Eye disorder—Doxorubicin—prostate cancer	1.27e-05	9.36e-05	CcSEcCtD
Lansoprazole—Tinnitus—Doxorubicin—prostate cancer	1.27e-05	9.34e-05	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Docetaxel—prostate cancer	1.26e-05	9.33e-05	CcSEcCtD
Lansoprazole—Cardiac disorder—Doxorubicin—prostate cancer	1.26e-05	9.3e-05	CcSEcCtD
Lansoprazole—Flatulence—Epirubicin—prostate cancer	1.26e-05	9.29e-05	CcSEcCtD
Lansoprazole—Tension—Epirubicin—prostate cancer	1.25e-05	9.25e-05	CcSEcCtD
Lansoprazole—Dysgeusia—Epirubicin—prostate cancer	1.25e-05	9.23e-05	CcSEcCtD
Lansoprazole—Nervousness—Epirubicin—prostate cancer	1.24e-05	9.15e-05	CcSEcCtD
Lansoprazole—Back pain—Epirubicin—prostate cancer	1.23e-05	9.12e-05	CcSEcCtD
Lansoprazole—Feeling abnormal—Capecitabine—prostate cancer	1.23e-05	9.1e-05	CcSEcCtD
Lansoprazole—Angiopathy—Doxorubicin—prostate cancer	1.23e-05	9.09e-05	CcSEcCtD
Lansoprazole—Dizziness—Etoposide—prostate cancer	1.23e-05	9.07e-05	CcSEcCtD
Lansoprazole—Muscle spasms—Epirubicin—prostate cancer	1.23e-05	9.06e-05	CcSEcCtD
Lansoprazole—Immune system disorder—Doxorubicin—prostate cancer	1.23e-05	9.05e-05	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Capecitabine—prostate cancer	1.22e-05	9.03e-05	CcSEcCtD
Lansoprazole—Mediastinal disorder—Doxorubicin—prostate cancer	1.22e-05	9.03e-05	CcSEcCtD
Lansoprazole—Abdominal pain—Docetaxel—prostate cancer	1.22e-05	9.02e-05	CcSEcCtD
Lansoprazole—Body temperature increased—Docetaxel—prostate cancer	1.22e-05	9.02e-05	CcSEcCtD
Lansoprazole—Chills—Doxorubicin—prostate cancer	1.22e-05	8.99e-05	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Prednisone—prostate cancer	1.21e-05	8.96e-05	CcSEcCtD
Lansoprazole—Arrhythmia—Doxorubicin—prostate cancer	1.21e-05	8.95e-05	CcSEcCtD
Lansoprazole—Insomnia—Prednisone—prostate cancer	1.2e-05	8.9e-05	CcSEcCtD
Lansoprazole—Vision blurred—Epirubicin—prostate cancer	1.2e-05	8.88e-05	CcSEcCtD
Lansoprazole—Alopecia—Doxorubicin—prostate cancer	1.2e-05	8.85e-05	CcSEcCtD
Lansoprazole—Paraesthesia—Prednisone—prostate cancer	1.2e-05	8.83e-05	CcSEcCtD
Lansoprazole—Mental disorder—Doxorubicin—prostate cancer	1.19e-05	8.78e-05	CcSEcCtD
Lansoprazole—Urticaria—Capecitabine—prostate cancer	1.19e-05	8.77e-05	CcSEcCtD
Lansoprazole—Ill-defined disorder—Epirubicin—prostate cancer	1.18e-05	8.74e-05	CcSEcCtD
Lansoprazole—Abdominal pain—Capecitabine—prostate cancer	1.18e-05	8.73e-05	CcSEcCtD
Lansoprazole—Body temperature increased—Capecitabine—prostate cancer	1.18e-05	8.73e-05	CcSEcCtD
Lansoprazole—Vomiting—Etoposide—prostate cancer	1.18e-05	8.72e-05	CcSEcCtD
Lansoprazole—Malnutrition—Doxorubicin—prostate cancer	1.18e-05	8.72e-05	CcSEcCtD
Lansoprazole—Erythema—Doxorubicin—prostate cancer	1.18e-05	8.72e-05	CcSEcCtD
Lansoprazole—Anaemia—Epirubicin—prostate cancer	1.18e-05	8.71e-05	CcSEcCtD
Lansoprazole—Agitation—Epirubicin—prostate cancer	1.17e-05	8.66e-05	CcSEcCtD
Lansoprazole—Dyspepsia—Prednisone—prostate cancer	1.17e-05	8.66e-05	CcSEcCtD
Lansoprazole—Rash—Etoposide—prostate cancer	1.17e-05	8.65e-05	CcSEcCtD
Lansoprazole—Dermatitis—Etoposide—prostate cancer	1.17e-05	8.64e-05	CcSEcCtD
Lansoprazole—Headache—Etoposide—prostate cancer	1.16e-05	8.6e-05	CcSEcCtD
Lansoprazole—Flatulence—Doxorubicin—prostate cancer	1.16e-05	8.59e-05	CcSEcCtD
Lansoprazole—Tension—Doxorubicin—prostate cancer	1.16e-05	8.56e-05	CcSEcCtD
Lansoprazole—Decreased appetite—Prednisone—prostate cancer	1.16e-05	8.55e-05	CcSEcCtD
Lansoprazole—Dysgeusia—Doxorubicin—prostate cancer	1.16e-05	8.54e-05	CcSEcCtD
Lansoprazole—Malaise—Epirubicin—prostate cancer	1.15e-05	8.5e-05	CcSEcCtD
Lansoprazole—Fatigue—Prednisone—prostate cancer	1.15e-05	8.48e-05	CcSEcCtD
Lansoprazole—Nervousness—Doxorubicin—prostate cancer	1.15e-05	8.47e-05	CcSEcCtD
Lansoprazole—Vertigo—Epirubicin—prostate cancer	1.15e-05	8.47e-05	CcSEcCtD
Lansoprazole—Syncope—Epirubicin—prostate cancer	1.14e-05	8.45e-05	CcSEcCtD
Lansoprazole—Leukopenia—Epirubicin—prostate cancer	1.14e-05	8.44e-05	CcSEcCtD
Lansoprazole—Back pain—Doxorubicin—prostate cancer	1.14e-05	8.44e-05	CcSEcCtD
Lansoprazole—Constipation—Prednisone—prostate cancer	1.14e-05	8.41e-05	CcSEcCtD
Lansoprazole—Hypersensitivity—Docetaxel—prostate cancer	1.14e-05	8.4e-05	CcSEcCtD
Lansoprazole—Muscle spasms—Doxorubicin—prostate cancer	1.14e-05	8.38e-05	CcSEcCtD
Lansoprazole—Palpitations—Epirubicin—prostate cancer	1.13e-05	8.33e-05	CcSEcCtD
Lansoprazole—Loss of consciousness—Epirubicin—prostate cancer	1.12e-05	8.28e-05	CcSEcCtD
Lansoprazole—Cough—Epirubicin—prostate cancer	1.11e-05	8.22e-05	CcSEcCtD
Lansoprazole—Vision blurred—Doxorubicin—prostate cancer	1.11e-05	8.22e-05	CcSEcCtD
Lansoprazole—Asthenia—Docetaxel—prostate cancer	1.11e-05	8.18e-05	CcSEcCtD
Lansoprazole—Convulsion—Epirubicin—prostate cancer	1.11e-05	8.17e-05	CcSEcCtD
Lansoprazole—Nausea—Etoposide—prostate cancer	1.1e-05	8.15e-05	CcSEcCtD
Lansoprazole—Hypertension—Epirubicin—prostate cancer	1.1e-05	8.14e-05	CcSEcCtD
Lansoprazole—Hypersensitivity—Capecitabine—prostate cancer	1.1e-05	8.13e-05	CcSEcCtD
Lansoprazole—Feeling abnormal—Prednisone—prostate cancer	1.1e-05	8.1e-05	CcSEcCtD
Lansoprazole—Ill-defined disorder—Doxorubicin—prostate cancer	1.1e-05	8.09e-05	CcSEcCtD
Lansoprazole—Pruritus—Docetaxel—prostate cancer	1.09e-05	8.07e-05	CcSEcCtD
Lansoprazole—Anaemia—Doxorubicin—prostate cancer	1.09e-05	8.06e-05	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Prednisone—prostate cancer	1.09e-05	8.04e-05	CcSEcCtD
Lansoprazole—Myalgia—Epirubicin—prostate cancer	1.09e-05	8.02e-05	CcSEcCtD
Lansoprazole—Chest pain—Epirubicin—prostate cancer	1.09e-05	8.02e-05	CcSEcCtD
Lansoprazole—Arthralgia—Epirubicin—prostate cancer	1.09e-05	8.02e-05	CcSEcCtD
Lansoprazole—Agitation—Doxorubicin—prostate cancer	1.09e-05	8.01e-05	CcSEcCtD
Lansoprazole—Anxiety—Epirubicin—prostate cancer	1.08e-05	8e-05	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	1.08e-05	7.97e-05	CcSEcCtD
Lansoprazole—Discomfort—Epirubicin—prostate cancer	1.07e-05	7.93e-05	CcSEcCtD
Lansoprazole—Asthenia—Capecitabine—prostate cancer	1.07e-05	7.92e-05	CcSEcCtD
Lansoprazole—Malaise—Doxorubicin—prostate cancer	1.07e-05	7.86e-05	CcSEcCtD
Lansoprazole—Dry mouth—Epirubicin—prostate cancer	1.06e-05	7.85e-05	CcSEcCtD
Lansoprazole—Vertigo—Doxorubicin—prostate cancer	1.06e-05	7.84e-05	CcSEcCtD
Lansoprazole—Syncope—Doxorubicin—prostate cancer	1.06e-05	7.82e-05	CcSEcCtD
Lansoprazole—Urticaria—Prednisone—prostate cancer	1.06e-05	7.81e-05	CcSEcCtD
Lansoprazole—Pruritus—Capecitabine—prostate cancer	1.06e-05	7.81e-05	CcSEcCtD
Lansoprazole—Leukopenia—Doxorubicin—prostate cancer	1.06e-05	7.81e-05	CcSEcCtD
Lansoprazole—Diarrhoea—Docetaxel—prostate cancer	1.06e-05	7.8e-05	CcSEcCtD
Lansoprazole—Abdominal pain—Prednisone—prostate cancer	1.05e-05	7.77e-05	CcSEcCtD
Lansoprazole—Body temperature increased—Prednisone—prostate cancer	1.05e-05	7.77e-05	CcSEcCtD
Lansoprazole—Confusional state—Epirubicin—prostate cancer	1.05e-05	7.76e-05	CcSEcCtD
Lansoprazole—Palpitations—Doxorubicin—prostate cancer	1.04e-05	7.71e-05	CcSEcCtD
Lansoprazole—Oedema—Epirubicin—prostate cancer	1.04e-05	7.69e-05	CcSEcCtD
Lansoprazole—Anaphylactic shock—Epirubicin—prostate cancer	1.04e-05	7.69e-05	CcSEcCtD
Lansoprazole—Loss of consciousness—Doxorubicin—prostate cancer	1.04e-05	7.66e-05	CcSEcCtD
Lansoprazole—Infection—Epirubicin—prostate cancer	1.04e-05	7.64e-05	CcSEcCtD
Lansoprazole—Cough—Doxorubicin—prostate cancer	1.03e-05	7.61e-05	CcSEcCtD
Lansoprazole—Shock—Epirubicin—prostate cancer	1.03e-05	7.57e-05	CcSEcCtD
Lansoprazole—Convulsion—Doxorubicin—prostate cancer	1.02e-05	7.56e-05	CcSEcCtD
Lansoprazole—Diarrhoea—Capecitabine—prostate cancer	1.02e-05	7.55e-05	CcSEcCtD
Lansoprazole—Nervous system disorder—Epirubicin—prostate cancer	1.02e-05	7.54e-05	CcSEcCtD
Lansoprazole—Dizziness—Docetaxel—prostate cancer	1.02e-05	7.54e-05	CcSEcCtD
Lansoprazole—Thrombocytopenia—Epirubicin—prostate cancer	1.02e-05	7.53e-05	CcSEcCtD
Lansoprazole—Hypertension—Doxorubicin—prostate cancer	1.02e-05	7.53e-05	CcSEcCtD
Lansoprazole—Tachycardia—Epirubicin—prostate cancer	1.02e-05	7.51e-05	CcSEcCtD
Lansoprazole—Skin disorder—Epirubicin—prostate cancer	1.01e-05	7.47e-05	CcSEcCtD
Lansoprazole—Hyperhidrosis—Epirubicin—prostate cancer	1.01e-05	7.44e-05	CcSEcCtD
Lansoprazole—Chest pain—Doxorubicin—prostate cancer	1.01e-05	7.42e-05	CcSEcCtD
Lansoprazole—Myalgia—Doxorubicin—prostate cancer	1.01e-05	7.42e-05	CcSEcCtD
Lansoprazole—Arthralgia—Doxorubicin—prostate cancer	1.01e-05	7.42e-05	CcSEcCtD
Lansoprazole—Anxiety—Doxorubicin—prostate cancer	1e-05	7.4e-05	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	9.99e-06	7.37e-05	CcSEcCtD
Lansoprazole—Discomfort—Doxorubicin—prostate cancer	9.94e-06	7.34e-05	CcSEcCtD
Lansoprazole—Anorexia—Epirubicin—prostate cancer	9.93e-06	7.33e-05	CcSEcCtD
Lansoprazole—Dizziness—Capecitabine—prostate cancer	9.89e-06	7.3e-05	CcSEcCtD
Lansoprazole—Dry mouth—Doxorubicin—prostate cancer	9.83e-06	7.26e-05	CcSEcCtD
Lansoprazole—Vomiting—Docetaxel—prostate cancer	9.82e-06	7.25e-05	CcSEcCtD
Lansoprazole—Hypersensitivity—Prednisone—prostate cancer	9.81e-06	7.25e-05	CcSEcCtD
Lansoprazole—Rash—Docetaxel—prostate cancer	9.74e-06	7.19e-05	CcSEcCtD
Lansoprazole—Hypotension—Epirubicin—prostate cancer	9.74e-06	7.19e-05	CcSEcCtD
Lansoprazole—Dermatitis—Docetaxel—prostate cancer	9.73e-06	7.18e-05	CcSEcCtD
Lansoprazole—Confusional state—Doxorubicin—prostate cancer	9.72e-06	7.18e-05	CcSEcCtD
Lansoprazole—Headache—Docetaxel—prostate cancer	9.68e-06	7.14e-05	CcSEcCtD
Lansoprazole—Oedema—Doxorubicin—prostate cancer	9.64e-06	7.12e-05	CcSEcCtD
Lansoprazole—Anaphylactic shock—Doxorubicin—prostate cancer	9.64e-06	7.12e-05	CcSEcCtD
Lansoprazole—Infection—Doxorubicin—prostate cancer	9.58e-06	7.07e-05	CcSEcCtD
Lansoprazole—Asthenia—Prednisone—prostate cancer	9.56e-06	7.06e-05	CcSEcCtD
Lansoprazole—Vomiting—Capecitabine—prostate cancer	9.51e-06	7.02e-05	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Epirubicin—prostate cancer	9.49e-06	7.01e-05	CcSEcCtD
Lansoprazole—Shock—Doxorubicin—prostate cancer	9.48e-06	7e-05	CcSEcCtD
Lansoprazole—Nervous system disorder—Doxorubicin—prostate cancer	9.45e-06	6.98e-05	CcSEcCtD
Lansoprazole—Thrombocytopenia—Doxorubicin—prostate cancer	9.44e-06	6.97e-05	CcSEcCtD
Lansoprazole—Rash—Capecitabine—prostate cancer	9.43e-06	6.96e-05	CcSEcCtD
Lansoprazole—Pruritus—Prednisone—prostate cancer	9.42e-06	6.96e-05	CcSEcCtD
Lansoprazole—Insomnia—Epirubicin—prostate cancer	9.42e-06	6.96e-05	CcSEcCtD
Lansoprazole—Dermatitis—Capecitabine—prostate cancer	9.42e-06	6.96e-05	CcSEcCtD
Lansoprazole—Tachycardia—Doxorubicin—prostate cancer	9.41e-06	6.95e-05	CcSEcCtD
Lansoprazole—Headache—Capecitabine—prostate cancer	9.37e-06	6.92e-05	CcSEcCtD
Lansoprazole—Skin disorder—Doxorubicin—prostate cancer	9.36e-06	6.91e-05	CcSEcCtD
Lansoprazole—Paraesthesia—Epirubicin—prostate cancer	9.36e-06	6.91e-05	CcSEcCtD
Lansoprazole—Hyperhidrosis—Doxorubicin—prostate cancer	9.32e-06	6.88e-05	CcSEcCtD
Lansoprazole—Dyspnoea—Epirubicin—prostate cancer	9.29e-06	6.86e-05	CcSEcCtD
Lansoprazole—Somnolence—Epirubicin—prostate cancer	9.26e-06	6.84e-05	CcSEcCtD
Lansoprazole—Anorexia—Doxorubicin—prostate cancer	9.19e-06	6.78e-05	CcSEcCtD
Lansoprazole—Nausea—Docetaxel—prostate cancer	9.18e-06	6.77e-05	CcSEcCtD
Lansoprazole—Dyspepsia—Epirubicin—prostate cancer	9.17e-06	6.77e-05	CcSEcCtD
Lansoprazole—Diarrhoea—Prednisone—prostate cancer	9.11e-06	6.73e-05	CcSEcCtD
Lansoprazole—Decreased appetite—Epirubicin—prostate cancer	9.06e-06	6.69e-05	CcSEcCtD
Lansoprazole—Hypotension—Doxorubicin—prostate cancer	9.01e-06	6.65e-05	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Epirubicin—prostate cancer	8.99e-06	6.64e-05	CcSEcCtD
Lansoprazole—Fatigue—Epirubicin—prostate cancer	8.98e-06	6.63e-05	CcSEcCtD
Lansoprazole—Constipation—Epirubicin—prostate cancer	8.91e-06	6.58e-05	CcSEcCtD
Lansoprazole—Pain—Epirubicin—prostate cancer	8.91e-06	6.58e-05	CcSEcCtD
Lansoprazole—Nausea—Capecitabine—prostate cancer	8.88e-06	6.56e-05	CcSEcCtD
Lansoprazole—Dizziness—Prednisone—prostate cancer	8.81e-06	6.5e-05	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Doxorubicin—prostate cancer	8.78e-06	6.48e-05	CcSEcCtD
Lansoprazole—Insomnia—Doxorubicin—prostate cancer	8.72e-06	6.44e-05	CcSEcCtD
Lansoprazole—Paraesthesia—Doxorubicin—prostate cancer	8.66e-06	6.39e-05	CcSEcCtD
Lansoprazole—Dyspnoea—Doxorubicin—prostate cancer	8.59e-06	6.35e-05	CcSEcCtD
Lansoprazole—Feeling abnormal—Epirubicin—prostate cancer	8.59e-06	6.34e-05	CcSEcCtD
Lansoprazole—Somnolence—Doxorubicin—prostate cancer	8.57e-06	6.33e-05	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Epirubicin—prostate cancer	8.52e-06	6.29e-05	CcSEcCtD
Lansoprazole—Dyspepsia—Doxorubicin—prostate cancer	8.49e-06	6.27e-05	CcSEcCtD
Lansoprazole—Vomiting—Prednisone—prostate cancer	8.47e-06	6.25e-05	CcSEcCtD
Lansoprazole—Rash—Prednisone—prostate cancer	8.4e-06	6.2e-05	CcSEcCtD
Lansoprazole—Dermatitis—Prednisone—prostate cancer	8.39e-06	6.2e-05	CcSEcCtD
Lansoprazole—Decreased appetite—Doxorubicin—prostate cancer	8.38e-06	6.19e-05	CcSEcCtD
Lansoprazole—Headache—Prednisone—prostate cancer	8.35e-06	6.16e-05	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Doxorubicin—prostate cancer	8.32e-06	6.14e-05	CcSEcCtD
Lansoprazole—Fatigue—Doxorubicin—prostate cancer	8.31e-06	6.14e-05	CcSEcCtD
Lansoprazole—Urticaria—Epirubicin—prostate cancer	8.28e-06	6.11e-05	CcSEcCtD
Lansoprazole—Constipation—Doxorubicin—prostate cancer	8.24e-06	6.09e-05	CcSEcCtD
Lansoprazole—Pain—Doxorubicin—prostate cancer	8.24e-06	6.09e-05	CcSEcCtD
Lansoprazole—Abdominal pain—Epirubicin—prostate cancer	8.24e-06	6.08e-05	CcSEcCtD
Lansoprazole—Body temperature increased—Epirubicin—prostate cancer	8.24e-06	6.08e-05	CcSEcCtD
Lansoprazole—Feeling abnormal—Doxorubicin—prostate cancer	7.94e-06	5.87e-05	CcSEcCtD
Lansoprazole—Nausea—Prednisone—prostate cancer	7.91e-06	5.84e-05	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Doxorubicin—prostate cancer	7.88e-06	5.82e-05	CcSEcCtD
Lansoprazole—Hypersensitivity—Epirubicin—prostate cancer	7.68e-06	5.67e-05	CcSEcCtD
Lansoprazole—Urticaria—Doxorubicin—prostate cancer	7.66e-06	5.65e-05	CcSEcCtD
Lansoprazole—Abdominal pain—Doxorubicin—prostate cancer	7.62e-06	5.63e-05	CcSEcCtD
Lansoprazole—Body temperature increased—Doxorubicin—prostate cancer	7.62e-06	5.63e-05	CcSEcCtD
Lansoprazole—Asthenia—Epirubicin—prostate cancer	7.48e-06	5.52e-05	CcSEcCtD
Lansoprazole—Pruritus—Epirubicin—prostate cancer	7.37e-06	5.44e-05	CcSEcCtD
Lansoprazole—Diarrhoea—Epirubicin—prostate cancer	7.13e-06	5.26e-05	CcSEcCtD
Lansoprazole—Hypersensitivity—Doxorubicin—prostate cancer	7.1e-06	5.24e-05	CcSEcCtD
Lansoprazole—Asthenia—Doxorubicin—prostate cancer	6.92e-06	5.11e-05	CcSEcCtD
Lansoprazole—Dizziness—Epirubicin—prostate cancer	6.89e-06	5.09e-05	CcSEcCtD
Lansoprazole—Pruritus—Doxorubicin—prostate cancer	6.82e-06	5.04e-05	CcSEcCtD
Lansoprazole—Vomiting—Epirubicin—prostate cancer	6.62e-06	4.89e-05	CcSEcCtD
Lansoprazole—Diarrhoea—Doxorubicin—prostate cancer	6.6e-06	4.87e-05	CcSEcCtD
Lansoprazole—Rash—Epirubicin—prostate cancer	6.57e-06	4.85e-05	CcSEcCtD
Lansoprazole—Dermatitis—Epirubicin—prostate cancer	6.56e-06	4.85e-05	CcSEcCtD
Lansoprazole—Headache—Epirubicin—prostate cancer	6.53e-06	4.82e-05	CcSEcCtD
Lansoprazole—Dizziness—Doxorubicin—prostate cancer	6.37e-06	4.71e-05	CcSEcCtD
Lansoprazole—Nausea—Epirubicin—prostate cancer	6.19e-06	4.57e-05	CcSEcCtD
Lansoprazole—Vomiting—Doxorubicin—prostate cancer	6.13e-06	4.53e-05	CcSEcCtD
Lansoprazole—Rash—Doxorubicin—prostate cancer	6.08e-06	4.49e-05	CcSEcCtD
Lansoprazole—Dermatitis—Doxorubicin—prostate cancer	6.07e-06	4.48e-05	CcSEcCtD
Lansoprazole—Headache—Doxorubicin—prostate cancer	6.04e-06	4.46e-05	CcSEcCtD
Lansoprazole—Nausea—Doxorubicin—prostate cancer	5.73e-06	4.23e-05	CcSEcCtD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	1.2e-06	1.3e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—NCOA1—prostate cancer	1.2e-06	1.3e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CYP3A4—prostate cancer	1.19e-06	1.3e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CYP17A1—prostate cancer	1.19e-06	1.3e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	1.18e-06	1.29e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CYP1B1—prostate cancer	1.18e-06	1.29e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—ERCC2—prostate cancer	1.18e-06	1.29e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CYP19A1—prostate cancer	1.18e-06	1.28e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—P4HB—prostate cancer	1.18e-06	1.28e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	1.17e-06	1.28e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CYP1B1—prostate cancer	1.17e-06	1.28e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—RXRA—prostate cancer	1.17e-06	1.27e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—TYMS—prostate cancer	1.16e-06	1.27e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PIK3CB—prostate cancer	1.16e-06	1.26e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—GSTM1—prostate cancer	1.15e-06	1.25e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PTGS2—prostate cancer	1.15e-06	1.25e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—GGT1—prostate cancer	1.14e-06	1.25e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—SLC22A1—prostate cancer	1.14e-06	1.25e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—NOS3—prostate cancer	1.14e-06	1.25e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—RXRA—prostate cancer	1.14e-06	1.24e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—GGT1—prostate cancer	1.13e-06	1.24e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.13e-06	1.24e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—NCOA2—prostate cancer	1.13e-06	1.24e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—LPL—prostate cancer	1.13e-06	1.23e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—NCOA1—prostate cancer	1.13e-06	1.23e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—COMT—prostate cancer	1.12e-06	1.22e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—GSTP1—prostate cancer	1.12e-06	1.22e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—NCOA1—prostate cancer	1.12e-06	1.22e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—SULT2A1—prostate cancer	1.11e-06	1.21e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CYP19A1—prostate cancer	1.11e-06	1.21e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—MTHFR—prostate cancer	1.11e-06	1.21e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CYP19A1—prostate cancer	1.1e-06	1.2e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—ITPR1—prostate cancer	1.1e-06	1.2e-05	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—PIK3CA—prostate cancer	1.1e-06	1.2e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—MED12—prostate cancer	1.1e-06	1.2e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—COMT—prostate cancer	1.1e-06	1.19e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—GSTP1—prostate cancer	1.09e-06	1.19e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—CYP1A1—prostate cancer	1.09e-06	1.19e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PPARA—prostate cancer	1.09e-06	1.19e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GNG5—prostate cancer	1.09e-06	1.19e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—ERCC2—prostate cancer	1.08e-06	1.18e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.08e-06	1.18e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—SLC5A5—prostate cancer	1.08e-06	1.18e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—ITPR1—prostate cancer	1.07e-06	1.17e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—RXRA—prostate cancer	1.07e-06	1.17e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—RXRA—prostate cancer	1.06e-06	1.16e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CYP2E1—prostate cancer	1.06e-06	1.15e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PIK3CB—prostate cancer	1.05e-06	1.15e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—NCOA3—prostate cancer	1.05e-06	1.14e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PTGS2—prostate cancer	1.04e-06	1.14e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—NQO1—prostate cancer	1.04e-06	1.14e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—TYMS—prostate cancer	1.04e-06	1.13e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.03e-06	1.13e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—COMT—prostate cancer	1.03e-06	1.13e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—TH—prostate cancer	1.03e-06	1.12e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—GSTP1—prostate cancer	1.03e-06	1.12e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—GSTM1—prostate cancer	1.03e-06	1.12e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—COMT—prostate cancer	1.02e-06	1.12e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—CAV1—prostate cancer	1.02e-06	1.12e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	1.02e-06	1.11e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—GSTP1—prostate cancer	1.02e-06	1.11e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CYP3A4—prostate cancer	1.02e-06	1.11e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—MTHFR—prostate cancer	1.02e-06	1.11e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—TYMS—prostate cancer	1.01e-06	1.11e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	1.01e-06	1.1e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—ITPR1—prostate cancer	1.01e-06	1.1e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—LPL—prostate cancer	1.01e-06	1.1e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—ITPR1—prostate cancer	1e-06	1.09e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—GSTM1—prostate cancer	1e-06	1.09e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PTEN—prostate cancer	1e-06	1.09e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CYP1B1—prostate cancer	1e-06	1.09e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—HPGDS—prostate cancer	9.99e-07	1.09e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PPARA—prostate cancer	9.97e-07	1.09e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CYP2C19—prostate cancer	9.93e-07	1.08e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	9.85e-07	1.07e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—LPL—prostate cancer	9.83e-07	1.07e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	9.77e-07	1.07e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CYP1A1—prostate cancer	9.73e-07	1.06e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ACHE—prostate cancer	9.69e-07	1.06e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GSTT1—prostate cancer	9.69e-07	1.06e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—GGT1—prostate cancer	9.69e-07	1.06e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—ERCC2—prostate cancer	9.65e-07	1.05e-05	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PIK3CA—prostate cancer	9.58e-07	1.05e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CYP2A6—prostate cancer	9.58e-07	1.04e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—TYMS—prostate cancer	9.55e-07	1.04e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—EP300—prostate cancer	9.55e-07	1.04e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—NCOA1—prostate cancer	9.54e-07	1.04e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CYP1A1—prostate cancer	9.5e-07	1.04e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—TYMS—prostate cancer	9.47e-07	1.03e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—GSTM1—prostate cancer	9.44e-07	1.03e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—ERCC2—prostate cancer	9.42e-07	1.03e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CYP19A1—prostate cancer	9.41e-07	1.03e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—CAV1—prostate cancer	9.38e-07	1.02e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—GSTM1—prostate cancer	9.36e-07	1.02e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—AKR1C3—prostate cancer	9.32e-07	1.02e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PIK3CG—prostate cancer	9.31e-07	1.02e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PRKACB—prostate cancer	9.27e-07	1.01e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—LPL—prostate cancer	9.27e-07	1.01e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—LPL—prostate cancer	9.19e-07	1e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CYP17A1—prostate cancer	9.17e-07	1e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PTEN—prostate cancer	9.11e-07	9.94e-06	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—RXRA—prostate cancer	9.08e-07	9.9e-06	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—MTHFR—prostate cancer	9.07e-07	9.89e-06	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	8.96e-07	9.77e-06	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—AKT1—prostate cancer	8.96e-07	9.77e-06	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CYP1A1—prostate cancer	8.95e-07	9.76e-06	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PPARA—prostate cancer	8.9e-07	9.71e-06	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—ERCC2—prostate cancer	8.88e-07	9.68e-06	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CYP1A1—prostate cancer	8.87e-07	9.68e-06	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—MTHFR—prostate cancer	8.85e-07	9.66e-06	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	8.83e-07	9.63e-06	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—INS—prostate cancer	8.82e-07	9.61e-06	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—ERCC2—prostate cancer	8.8e-07	9.6e-06	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—COMT—prostate cancer	8.75e-07	9.54e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—NCOA2—prostate cancer	8.74e-07	9.53e-06	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—GSTP1—prostate cancer	8.7e-07	9.49e-06	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—EP300—prostate cancer	8.69e-07	9.47e-06	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PPARA—prostate cancer	8.69e-07	9.47e-06	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—CREBBP—prostate cancer	8.64e-07	9.42e-06	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ITPR1—prostate cancer	8.56e-07	9.34e-06	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PIK3CG—prostate cancer	8.54e-07	9.31e-06	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	8.42e-07	9.18e-06	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CAV1—prostate cancer	8.37e-07	9.13e-06	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—MTHFR—prostate cancer	8.34e-07	9.1e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—SLC5A5—prostate cancer	8.34e-07	9.09e-06	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—MTHFR—prostate cancer	8.27e-07	9.02e-06	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PIK3CD—prostate cancer	8.19e-07	8.93e-06	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PPARA—prostate cancer	8.19e-07	8.93e-06	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CAV1—prostate cancer	8.17e-07	8.91e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CYP2E1—prostate cancer	8.15e-07	8.88e-06	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PPARA—prostate cancer	8.12e-07	8.85e-06	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—TYMS—prostate cancer	8.09e-07	8.82e-06	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—INS—prostate cancer	8.08e-07	8.81e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—NQO1—prostate cancer	8.05e-07	8.78e-06	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—GSTM1—prostate cancer	8e-07	8.72e-06	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	7.99e-07	8.72e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—TH—prostate cancer	7.94e-07	8.66e-06	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—CREBBP—prostate cancer	7.92e-07	8.63e-06	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—LPL—prostate cancer	7.85e-07	8.56e-06	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—AKT1—prostate cancer	7.83e-07	8.54e-06	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—NOS3—prostate cancer	7.73e-07	8.43e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CYP1B1—prostate cancer	7.72e-07	8.42e-06	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CAV1—prostate cancer	7.7e-07	8.39e-06	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CAV1—prostate cancer	7.63e-07	8.32e-06	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PIK3CG—prostate cancer	7.62e-07	8.31e-06	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CYP1A1—prostate cancer	7.58e-07	8.27e-06	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ERCC2—prostate cancer	7.52e-07	8.2e-06	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PIK3CD—prostate cancer	7.51e-07	8.19e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GGT1—prostate cancer	7.48e-07	8.15e-06	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PIK3CG—prostate cancer	7.44e-07	8.11e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—NCOA1—prostate cancer	7.37e-07	8.03e-06	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	7.29e-07	7.95e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CYP19A1—prostate cancer	7.26e-07	7.92e-06	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—INS—prostate cancer	7.22e-07	7.87e-06	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PIK3CB—prostate cancer	7.14e-07	7.78e-06	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—NOS3—prostate cancer	7.09e-07	7.73e-06	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PTGS2—prostate cancer	7.07e-07	7.71e-06	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—MTHFR—prostate cancer	7.07e-07	7.71e-06	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CREBBP—prostate cancer	7.07e-07	7.71e-06	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PIK3CA—prostate cancer	7.07e-07	7.7e-06	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—INS—prostate cancer	7.04e-07	7.68e-06	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PIK3CG—prostate cancer	7.01e-07	7.64e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—RXRA—prostate cancer	7.01e-07	7.64e-06	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PIK3CG—prostate cancer	6.95e-07	7.58e-06	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PPARA—prostate cancer	6.94e-07	7.56e-06	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CREBBP—prostate cancer	6.9e-07	7.52e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—COMT—prostate cancer	6.75e-07	7.36e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GSTP1—prostate cancer	6.72e-07	7.32e-06	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PIK3CD—prostate cancer	6.7e-07	7.31e-06	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—INS—prostate cancer	6.64e-07	7.24e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ITPR1—prostate cancer	6.61e-07	7.21e-06	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—INS—prostate cancer	6.58e-07	7.17e-06	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PIK3CB—prostate cancer	6.54e-07	7.14e-06	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PIK3CD—prostate cancer	6.54e-07	7.13e-06	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CAV1—prostate cancer	6.52e-07	7.11e-06	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CREBBP—prostate cancer	6.5e-07	7.09e-06	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PTGS2—prostate cancer	6.48e-07	7.07e-06	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CREBBP—prostate cancer	6.44e-07	7.03e-06	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PIK3CA—prostate cancer	6.43e-07	7.01e-06	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—NOS3—prostate cancer	6.33e-07	6.9e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—TYMS—prostate cancer	6.25e-07	6.81e-06	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	6.23e-07	6.79e-06	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—NOS3—prostate cancer	6.18e-07	6.73e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GSTM1—prostate cancer	6.17e-07	6.73e-06	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PTEN—prostate cancer	6.17e-07	6.73e-06	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PIK3CD—prostate cancer	6.16e-07	6.72e-06	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PIK3CD—prostate cancer	6.11e-07	6.66e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—LPL—prostate cancer	6.06e-07	6.61e-06	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PIK3CG—prostate cancer	5.94e-07	6.48e-06	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—EP300—prostate cancer	5.88e-07	6.41e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CYP1A1—prostate cancer	5.85e-07	6.38e-06	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PIK3CB—prostate cancer	5.84e-07	6.37e-06	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—NOS3—prostate cancer	5.82e-07	6.35e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ERCC2—prostate cancer	5.8e-07	6.33e-06	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PTGS2—prostate cancer	5.79e-07	6.31e-06	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—AKT1—prostate cancer	5.77e-07	6.29e-06	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—NOS3—prostate cancer	5.77e-07	6.29e-06	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PIK3CB—prostate cancer	5.7e-07	6.22e-06	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PTEN—prostate cancer	5.65e-07	6.17e-06	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PTGS2—prostate cancer	5.65e-07	6.16e-06	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—INS—prostate cancer	5.62e-07	6.13e-06	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CREBBP—prostate cancer	5.51e-07	6e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—MTHFR—prostate cancer	5.46e-07	5.95e-06	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—EP300—prostate cancer	5.39e-07	5.88e-06	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PIK3CB—prostate cancer	5.37e-07	5.86e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PPARA—prostate cancer	5.35e-07	5.84e-06	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PIK3CB—prostate cancer	5.33e-07	5.81e-06	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PTGS2—prostate cancer	5.32e-07	5.8e-06	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PTGS2—prostate cancer	5.28e-07	5.75e-06	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—AKT1—prostate cancer	5.25e-07	5.73e-06	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PIK3CD—prostate cancer	5.22e-07	5.69e-06	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PTEN—prostate cancer	5.05e-07	5.5e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CAV1—prostate cancer	5.03e-07	5.49e-06	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—NOS3—prostate cancer	4.93e-07	5.38e-06	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PTEN—prostate cancer	4.93e-07	5.37e-06	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—EP300—prostate cancer	4.81e-07	5.25e-06	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—EP300—prostate cancer	4.7e-07	5.12e-06	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PTEN—prostate cancer	4.64e-07	5.06e-06	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PTEN—prostate cancer	4.6e-07	5.02e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PIK3CG—prostate cancer	4.58e-07	5e-06	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PIK3CB—prostate cancer	4.55e-07	4.96e-06	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PTGS2—prostate cancer	4.51e-07	4.92e-06	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—EP300—prostate cancer	4.43e-07	4.83e-06	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—EP300—prostate cancer	4.39e-07	4.79e-06	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PIK3CA—prostate cancer	4.35e-07	4.74e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—INS—prostate cancer	4.34e-07	4.73e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CREBBP—prostate cancer	4.25e-07	4.63e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PIK3CD—prostate cancer	4.03e-07	4.39e-06	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PIK3CA—prostate cancer	3.99e-07	4.35e-06	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PTEN—prostate cancer	3.93e-07	4.29e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—NOS3—prostate cancer	3.81e-07	4.15e-06	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—EP300—prostate cancer	3.75e-07	4.09e-06	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PIK3CA—prostate cancer	3.56e-07	3.88e-06	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—AKT1—prostate cancer	3.55e-07	3.88e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PIK3CB—prostate cancer	3.51e-07	3.83e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PTGS2—prostate cancer	3.48e-07	3.79e-06	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PIK3CA—prostate cancer	3.48e-07	3.79e-06	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PIK3CA—prostate cancer	3.27e-07	3.57e-06	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—AKT1—prostate cancer	3.26e-07	3.55e-06	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PIK3CA—prostate cancer	3.25e-07	3.54e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PTEN—prostate cancer	3.04e-07	3.31e-06	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—AKT1—prostate cancer	2.91e-07	3.17e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—EP300—prostate cancer	2.89e-07	3.16e-06	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—AKT1—prostate cancer	2.84e-07	3.1e-06	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PIK3CA—prostate cancer	2.77e-07	3.03e-06	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—AKT1—prostate cancer	2.68e-07	2.92e-06	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—AKT1—prostate cancer	2.65e-07	2.89e-06	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—AKT1—prostate cancer	2.27e-07	2.47e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PIK3CA—prostate cancer	2.14e-07	2.33e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—AKT1—prostate cancer	1.75e-07	1.91e-06	CbGpPWpGaD
